WIPOSchützen Sie diese Marke vor Nachahmern!
Mit unserer Markenüberwachung werden Sie automatisch per E-Mail über Nachahmer und Trittbrettfahrer benachrichtigt.
Die Internationale Marke INTRABIO wurde als Wortmarke am 14.02.2018 bei der Weltorganisation für geistiges Eigentum angemeldet.
| Markenform | Wortmarke |
| Aktenzeichen | 1401943 |
| Registernummer | 017126384 |
| Länder | 
|
| Basismarke |
Nr. 017126384,
13. Dezember 2017
|
| Anmeldedatum | 14. Februar 2018 |
| Ablaufdatum | 14. Februar 2028 |
Markeninhaber
Summit House,
170 Finchley Road
GB
170 Finchley Road
GB
Markenvertreter
Dashwood,
69 Old Broad Street
GB
Waren und Dienstleistungen
05
Pharmaceutical preparations; pharmaceutical preparations for
activating cellular function; pharmaceutical preparations
for the prevention of diseases of the nervous system;
pharmaceutical preparations for treating sensory organ
disorders; pharmaceutical preparations for use in the
prevention and treatment of neurodegenerative diseases;
pharmaceutical preparations for use in the prevention and
treatment of neurodegenerative diseases, namely lysosomal
storage disorders, niemann-pick disease, alzheimer's
disease, parkinson's disease, prion disease, motor neurone
disease, huntington's disease, spinocerebellar ataxia and
spinal muscular atrophy; drugs for medical purposes; drugs
for medical purposes, namely the prevention and treatment of
neurodegenerative diseases; drugs for medical purposes,
namely the prevention and treatment of neurodegenerative
diseases, namely lysosomal storage disorders, niemann-pick
disease, alzheimer's disease, parkinson's disease, prion
disease, motor neurone disease, huntington's disease,
spinocerebellar ataxia and spinal muscular atrophy; reagents
for use in medical genetic testing; diagnostic reagents for
medical laboratory use; diagnostic reagents for medical
laboratory use, namely use in the detection and
identification of neurodegenerative diseases; diagnostic
reagents for medical laboratory use, namely use in the
detection and identification of neurodegenerative diseases,
namely lysosomal storage disorders, niemann-pick disease,
alzheimer's disease, parkinson's disease, prion disease,
motor neurone disease, huntington's disease, spinocerebellar
ataxia and spinal muscular atrophy; amino acid preparations
for medical purposes; amino acid preparations for
pharmaceutical use
42
Scientific and technological services and research and
design relating thereto; industrial analysis and research
services; scientific and technological services and research
in the field of neurodegenerative diseases, namely lysosomal
storage disorders, niemann-pick disease, alzheimer's
disease, parkinson's disease, prion disease, motor neurone
disease, huntington's disease, spinocerebellar ataxia and
spinal muscular atrophy; industrial analysis and research
services related to neurodegenerative diseases, namely
lysosomal storage disorders, niemann-pick disease,
alzheimer's disease, parkinson's disease, prion disease,
motor neurone disease, huntington's disease, spinocerebellar
ataxia and spinal muscular atrophy, design and development
of computer hardware and software related to assays;
clinical trials; conducting clinical trials for
pharmaceutical products; conducting clinical trials for
neurodegenerative diseases, namely lysosomal storage
disorders, niemann-pick disease, alzheimer's disease,
parkinson's disease, prion disease, motor neurone disease,
huntington's disease, spinocerebellar ataxia and spinal
muscular atrophy; medical laboratories for research related
to neurodegenerative diseases, namely lysosomal storage
disorders, niemann-pick disease, alzheimer's disease,
parkinson's disease, prion disease, motor neurone disease,
huntington's disease, spinocerebellar ataxia and spinal
muscular atrophy; providing information about the results of
clinical trials for pharmaceutical products; clinical
research; medical laboratories; research relating to
molecular sciences; medical research; genetic research;
research in the field of gene therapy; biopharmaceutical
research for development of targeted therapies for use in
the treatment of carcinomas and neurodegenerative diseases;
scientific, biochemical, research and development services
in the field of neurodegenerative diseases; providing
scientific information in the field of medical disorders and
their treatment; pharmaceutical drug development services
Die Bezeichnungen wurden automatisch übersetzt. Übersetzung anzeigen
Markenhistorie
| Datum | Belegnummer | Bereich | Eintrag |
|---|---|---|---|
| 10. Januar 2020 | 2020/3 Gaz | US | Ablehnung |
| 14. Juni 2018 | 2018/24 Gaz | US | Ablehnung |
| 14. Februar 2018 | 2018/18 Gaz | EM | Eintragung |
ID: 141401943